Breast cancer, ductal carcinoma diagnosis and treatment strategies for oncologists and healthcare professionals

A selection of must-have articles

The Risk of Early Recurrence and Distant Metastases—Lessons from the Monotherapy Adjuvant Aromatase Inhibitor Trials with a Focus on BIG 1–98

Worldwide, breast cancer is the most common form of cancer in women.

Reducing the Risk of Late Relapse in Postmenopausal Women with Hormone-sensitive Breast Cancer – Extended Adjuvant Letrozole

The risk of breast cancer recurrence continues even after primary management with surgery and/or chemotherapy.

Role of Radiotherapy in Patients with Early Breast Cancer

Studies have shown that radiotherapy can reduce both tumor burden and risk of tumor recurrence in various circumstances, and has played an integral role in the conservative management of early breast cancer.

Caelyx Adjuvant in Elderly Breast Cancer
An open label Phase II Trial to investigate the cardiac effects of pegylated liposomal doxorubicine (Caelyx) in elderly breast cancer patients with imaging and biochemical techniques. This is an open label Phase II study in elderly patients (65y or older) with early breast cancer who are candidate for adjuvant chemotherapy.

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer

High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer

Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study

Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study
Determination of guidelines regarding the use of adjuvant chemotherapy for early breast cancer in this population of Patients over 70 years old.

Capecitabine: a review

Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions

The role of capecitabine in first-line treatment for patients with metastatic breast cancer

Treatment for anthracycline-pretreated metastatic breast cancer

Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial

ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment
The purpose of this study is to compare disease free survival of elderly breast cancer patients treated with standard adjuvant chemotherapy (CMF) vs. experimental adjuvant chemotherapy (weekly docetaxel).

Capecitabine: a review

Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer

Treatment for anthracycline-pretreated metastatic breast cancer

Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?

Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer

Newly FDA-approved drugs

Tykerb TYKERB(R)(lapatinib), in combination with Xeloda(R)(capecitabine)
Company: GlaxoSmithKline
Approved: March 13, 2007
Approvals process

Treatment for: advanced or metastatic breast cancer
TYKERB(R) (lapatinib), in combination with Xeloda(R) (capecitabine) is approved for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. It is the first targeted, once-daily oral treatment option for this patient population.

FDA Approves Tykerb in Combination With Xeloda (capecitabine) for the Treatment of Advanced or Metastatic Breast Cancer in Women Who Have Progressed on Prior Therapy

Articles :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Companies :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Events :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Keywords :	a b c d e f g h i j k l m n o p q r s t u v w x y z
Specialities :	Brain Tumor Breast Cancer Cervical Cancer Colorectal Cancer Endometrial Cancer Gastrointestinal Cancer Genitourinary Cancer Leukemia Lung Cancer Ovarian Cancer
Other Touch Group sites:	Cardiology - Endocrine Disease - Oncological Disease - Gastroenterology - Respiratory Disease

The Risk of Early Recurrence and Distant Metastases—Lessons from the Monotherapy Adjuvant Aromatase Inhibitor Trials with a Focus on BIG 1–98

Reducing the Risk of Late Relapse in Postmenopausal Women with Hormone-sensitive Breast Cancer – Extended Adjuvant Letrozole

Role of Radiotherapy in Patients with Early Breast Cancer

Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma